The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | The impact of IDH mutated clones in NPM1+ AML
Curtis Lachowiez, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from a study investigating the clonal hierarchy of NPM1-mutated/IDH-mutated (NPM1+/IDH+) acute myeloid leukemia (AML), the predictive value of IDH mutations in NPM1+ AML, and the dynamics of IDH mutations during treatment using next-generation sequencing (NGS). In this study, 18% and 23% of patients with NPM1+ AML carried IDH1 and IDH2 mutations respectively, and IDH1+ was sub-clonal in 40% of cases. It was found that IDH1 and IDH2 mutations develop at different time points during leukemogenesis. Indeed, whilst IDH1+ was mostly sub-clonal and cleared in remission, IDH2+ often preceded NPM1 and persisted in remission. In addition, NPM1+/IDH+ was associated with improved overall survival (OS) and event-free survival (EFS) in patients receiving either standard intensive or venetoclax-based treatment regimens, especially in patients with IDH2 mutations. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
